DOT to include synthetic opioids in 5 panel drug test

Jan 27, 2017 0 Comments in Uncategorized by


Reminder of the week:

DOT to include synthetic opioids in 5 panel drug test

Effective October 1, 2017 

The Department of Transportation is proposing to amend its drug-testing program regulation to add four opioids (hydrocodone, hydromorphone, oxymorphone, and oxycodone) to its drug-testing panel;add methylenedioxyamphetamine (MDA) as an initial test analyte; and remove methylenedioxyethylamphetamine, (MDEA) as a confirmatory test analyte.

Currently, DOT regulations mandate urine testing under a five-panel test. We propose to maintain the current five panel test, but would rename the existing opiates category in § 40.85 from ‘‘opiates’’ to ‘‘opioids’’ to include the new HHS-mandated drugs. Opiates are derived from opium poppy plant alkaloid compounds, and include codeine and morphine. Heroin is produced by acetylation of morphine. Opioids is a broader term but, for purposes of Part 40, includes only opiate and semi-synthetic compounds (i.e., hydrocodone, hydromorphone, oxycodone, and oxymorphone). Semisynthetic opioids interact with the body’s chemical system in the same way as natural opiates (e.g. codeine, morphine, and heroin) and produce similar effects. Misuse, abuse, opioid use disorder (addiction), and overdose are potential dangers related to prescription opioids.

The proposed revision of the drug testing panel is intended to harmonize with the revised Mandatory Guidelines established by the U.S. Department of Health and Human Services for Federal drug-testing programs for urine testing.

Thank You and Be Safe Out There! 

Klemens Kuqi 

Compliance Manager